S. McCallister

发表

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate

K. Blennow, H. Zetterberg, R. Price, 2019, PloS one.

Measurement of plasma HIV-1 RNA below the limit of quantification (<20 copies/mL) of commercial assays with the integrase HIV RNA single-copy assay.

J. Mellors, N. Margot, C. Callebaut, 2018, Journal of Clinical Virology.

Efficacy of oral tenofovir alafenamide/emtricitabine combination or single agent tenofovir alafenamide against vaginal SHIV infection in macaques.

W. Heneine, J. Rooney, Yeojin Park, 2019, The Journal of infectious diseases.

Evaluation of soil top-cover systems to minimize infiltration into a sanitary landfill: A case study

R. Mansell, S. McCallister, Olaf L. Weeks, 1992 .

Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV

V. Soriano, D. Dieterich, J. Rockstroh, 2013, Annals of Internal Medicine.

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

J. van Lunzen, M. Cavassini, C. Orkin, 2016, The Lancet. Infectious diseases.

Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens: 80-Week Data From a Phase 2 Study

M. Markowitz, H. Valdez, D. Mayers, 2007, Journal of acquired immune deficiency syndromes.

Pharmacokinetic Characterization of Three Doses of Tipranavir Boosted with Ritonavir on Highly Active Antiretroviral Therapy in Treatment-Experienced HIV-1 Patients

F. Goebel, T. Macgregor, J. Sabo, 2010, HIV clinical trials.

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment Week 144 Results

P. Sax, M. Das, A. Clarke, 2017, Journal of acquired immune deficiency syndromes.

Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers

T. Macgregor, S. Norris, L. Galitz, 2004, HIV clinical trials.

Non-peptidic protease inhibitors (NPPIs): Tipranavir

D. Mayers, S. McCallister, V. Kohlbrenner, 2003 .

Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial

G. Doncel, I. McGowan, A. Thurman, 2021, EClinicalMedicine.

Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.

M. Ramgopal, E. Dejesus, S. Segal-Maurer, 2018, AIDS research and human retroviruses.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.

Michael R. Kramer, P. Sullivan, J. Guest, 2018, Annals of epidemiology.

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults

J. Gallant, M. Das, S. Oka, 2016, Journal of Acquired Immune Deficiency Syndromes.

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

K. Lichtenstein, F. Post, Samir K. Gupta, 2016, Journal of acquired immune deficiency syndromes.

Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues

A. Peery, J. Rooney, C. Gay, 2017, The Journal of antimicrobial chemotherapy.

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

J. Gallant, M. Das, P. Tebas, 2017, Journal of acquired immune deficiency syndromes.

P100 Tenofovir alafenamide (TAF) in a single tablet regimen in initial HIV-1 therapy

D. Podzamczer, D. Wohl, J. Molina, 2015, Sexually Transmitted Infections.

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

D. Podzamczer, P. Sax, M. Saag, 2015, The Lancet.

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study

P. Sax, A. Zolopa, F. Post, 2014, Journal of acquired immune deficiency syndromes.

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

C. Farthing, D. Cooper, S. Walmsley, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

K. Kitrinos, M. Fordyce, N. Margot, 2016, HIV clinical trials.

Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1-Infected Virologically Suppressed Adults

A. Lazzarin, A. Rachlis, A. Cheng, 2015 .

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

M. Saag, M. Das, J. Flamm, 2015, Journal of Acquired Immune Deficiency Syndromes.

The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.

Michael R. Kramer, P. Sullivan, J. Guest, 2018, Annals of epidemiology.

Loiasis in a peace corps volunteer from zaire

J. Flaherty, S. McCallister, 1993 .

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART

A. Landay, B. Patterson, K. Shults, 2001, AIDS.

Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012-2016.

P. Sullivan, L. Waller, B. Cadwell, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.

Michael R. Kramer, P. Sullivan, A. Siegler, 2020, Annals of epidemiology.

Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.

Michael R. Kramer, P. Sullivan, A. Siegler, 2020, Annals of epidemiology.

Estimation of new HIV diagnosis rates among high‐risk, PrEP‐eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States

J. Baeten, M. Das, S. Scheer, 2019, Journal of the International AIDS Society.

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

H. Jessen, R. Grant, K. Mounzer, 2020, The Lancet.

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.

P. Anderson, Lane R. Bushman, S. MaWhinney, 2020, Journal of acquired immune deficiency syndromes.

Adherence to Daily Oral TDF/FTC for PrEP in Community Health Center Populations: The Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study

J. Wiener, N. Glick, L. Mena, 2021, AIDS and Behavior.

Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials.

M. Wulfsohn, K. White, Lijie Zhong, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide

T. Bannerman, M. Das, G. McComsey, 2016, EBioMedicine.

A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1–Infected Patients

T. Macgregor, H. Valdez, M. Borin, 2004, Journal of acquired immune deficiency syndromes.

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate

M. Das, P. Hsue, J. Baril, 2019, Open forum infectious diseases.

Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers

T. Macgregor, T. Heming, D. Hoelscher, 2005, Antimicrobial Agents and Chemotherapy.

P074 Significant efficacy and long term safety difference with taf-based str in naïve adults

P. Sax, M. Das, J. Arribas, 2017 .

Susceptibility of Diverse HIV-1 Patient Isolates to the Maturation Inhibitor, Bevirimat (MPC-4326*), is Determined by Clade- Specific Polymorphisms in Gag CA-SP1

David E. Martin, François Hamy, T. Klimkait, 2009 .

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.

M. Das, N. Margot, C. Callebaut, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Infrequent Development of Drug Resistance in HIV-1-Infected Treatment-Naive Subjects after 96 Weeks of Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate

M. Das, N. Margot, C. Callebaut, 2017, Antiviral therapy.

Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials

Ouzama Henry, S. McCallister, S. Sampson, 2023, Clinical trials.

D. Podzamczer, P. Sax, M. Saag, 2015, The Lancet.